DOTA-LM3 TFA

DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist with the molecular structure p-Cl-Phe-cyclo (D-Cys-Tyr-D-4-amino-Phe (carbamoyl) -Lys-Thr-Cys) D-Tyr-NH2, used for in vivo tumor tracing via isotopic labeling, such as 177Lu-DOTA-LM3 TFA and 68Ga-DOTA-LM3 TFA. The 68Ga-labeled compound shows favorable biodistribution, high tumor uptake, good tumor retention, and minimal safety concerns, while the 177Lu-labeled variant targets DOTATOC-negative liver metastases, including pancreatic NET and extensive tumor thrombosis [1] [2].